mm1313亚洲精品,欧美俄罗斯40老熟妇,欧美日韩在线观看视频在线,亚洲欧美国产激情综合在线

掃碼關(guān)注公眾號(hào)           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  關(guān)于我們  聯(lián)系我們
99久久国产热精品,日本一区二区啪啪视频,亚洲国产成人av一区
首頁(yè) > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
FGD3 Rabbit pAb (bs-16079R)  
訂購(gòu)熱線:400-901-9800
訂購(gòu)郵箱:sales@m.p2b3.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@m.p2b3.cn
50ul/1180.00元
100ul/1980.00元
200ul/2800.00元
大包裝/詢價(jià)

產(chǎn)品編號(hào) bs-16079R
英文名稱 FGD3 Rabbit pAb
中文名稱 FGD3蛋白抗體
別    名 Faciogenital dysplasia 3; FGD1 family, member 3; FGD3; FGD3_HUMAN; FYVE; FYVE, RhoGEF and PH domain containing 3; FYVE, RhoGEF and PH domain containing protein 3; RhoGEF and PH domain-containing protein 3; ZFYVE5; Zinc finger FYVE domain containing protei  
研究領(lǐng)域 細(xì)胞生物  信號(hào)轉(zhuǎn)導(dǎo)  細(xì)胞膜受體  G蛋白偶聯(lián)受體  G蛋白信號(hào)  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human,Mouse (predicted: Rat)
產(chǎn)品應(yīng)用 WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 79 kDa
檢測(cè)分子量
細(xì)胞定位 細(xì)胞漿 
性    狀 Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human FGD3: 501-600/725 
亞    型 IgG
純化方法 affinity purified by Protein A
緩 沖 液 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
注意事項(xiàng) This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹 FGD1 gene mutations result in faciogenital dysplasia (FGDY, Aarskog-Scott syndrome), an X-linked developmental disorder that adversely affects the formation of multiple skeletal structures. FGD1 maps to human chromosome Xp11.21 and shares a high degree of sequence identity with the FGD2 (6p21.2) and the FGD3 (9q22.31) proteins. FGD1 encodes a guanine nucleotide exchange factor that specifically activates the Rho GTPase Cdc42. FGD2 is present in several diverse tissues during embryogenesis, suggesting a role in embryonic development. FGD3 stimulates fibroblasts to form filopodia, which are Actin microspikes formed upon the stimulation of Cdc42. All FGD family members contain equivalent signaling domains and a conserved structural organization, which strongly suggests that these signaling domains form a canonical core structure for members of the FGD family of RhoGEF proteins. These proteins control essential signals required during embryonic development.

Function:
Promotes the formation of filopodia. May activate CDC42, a member of the Ras-like family of Rho- and Rac proteins, by exchanging bound GDP for free GTP. Plays a role in regulating the actin cytoskeleton and cell shape.

Subcellular Location:
Cytoplasm. Cytoplasm > cytoskeleton.

Similarity:
Contains 1 DH (DBL-homology) domain.
Contains 1 FYVE-type zinc finger.
Contains 2 PH domains.

SWISS:
Q5JSP0

Gene ID:
89846

Database links:

Entrez Gene: 89846 Human

Entrez Gene: 30938 Mouse

Entrez Gene: 361223 Rat

SwissProt: Q5JSP0 Human

SwissProt: O88842 Mouse

Unigene: 411081 Human

Unigene: 291089 Mouse

Unigene: 214480 Rat



產(chǎn)品圖片
Sample: 293T Cell (Human) Lysate at 40 ug Primary: Anti-FGD3 (bs-16079R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 79 kD Observed band size: 75 kD
Paraformaldehyde-fixed, paraffin embedded Mouse Stomach; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with FGD3 Polyclonal Antibody, Unconjugated (bs-16079R) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.
版權(quán)所有 2004-2026 www.m.p2b3.cn 北京博奧森生物技術(shù)有限公司
通過國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號(hào): 00124Q34771R2M/1100
通過國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |